Santhera schliesst exclusive Liefervertrag für AGAMREE® (Vamorolon) with the Ali Al Suwaidi Trading Establishment (ASTE) in Qatar ab

Pratteln, Switzerland, November 12, 2024 – Santhera Pharmaceuticals (SIX: SANN) has granted an exclusive license to Ali Al Suwaidi Trading Est. (ASTE) for the treatment of patients with Duchenne Muscular Dystrophy (DMD) with AGAMREE in the treatment of a named patient program.

The Vereinbarung is light from ASTE, a healthcare pioneer with four-year treatment in Qatar, continuing the unfunded care of DMD patients in the region. As a Vertriebspartner of AGAMREE for catariek Gesundheitseinrichtungen with ASTE with Santhera sister work, a Betreuung der Patients in the Rahmen of the Named-Patient-Programs of unterstützen.

“This Vertriebsvereinbarung with ASTE marks a new date that Meilenstein for Santhera, which means that the second generation of AGAMREE will be available. While collaborating with expert organizations, which have a wide variety of specialist markets, they can make an optimal choice for the patients,” says Geert Jan van Daal, MD, PhD, Chief Commercial Officer von Santhera. “These things suggest that another region is written in another region and take the next step, AGAMREE for Duchenne Patients to be improved.”

“As a long-term distributor in the medical health sector, we have been working with care for patients with Duchenne Muscular Dystrophy for their innovative treatment,” says Ali Mohamed Al-Suwaidi, Chairman of Ali Al Suwaidi Trading Est. ‘If you want to do one of the most important things in the research of specialization and our research into healthcare in your country, it is wise to set a certain goal, so that AGAMREE understands the patients, who are most important. These products complete the perfect mission and provide innovative solutions for the cataract market.”

Über AGAMREE® (Vamorolon)
AGAMREE is a new device with a twist mechanism, which works on the binding and close range at a discount, but it is possible that the action will be changed. This is an essential substrate for the 11-β-Hydroxysteroid Dehydrogenase (11β-HSD) Enzyme, which is responsible for the local activity level and the short steroid association toxin in local compounds during the duration (1-4). This mechanism has the potential to break up the steroids, we will use AGAMREE as a dissociative agent and alternative to the best short steroids, of the standard therapy for children and adolescents with DMD, positioned (1-4).

In the relevant VISION-DMD study, AGAMREE is the first endpoint of the upward path (TTSTAND) in the placebo study (p = 0.002) after 24 studies and a clear Sicherheits and Vertraglichkeitsprofil (1, 4). Die am häufsten reportedeten Nebenwirkungen were cushingoides Aussehen, Erbrechen, Wetzunahme und Reizbarkeit. I was all the Nebenwirkungen von leichtem bis mittlerem Schweregrad.

The respective data, which AGAMREE in the short steroids of the guard are not einschränkt (5) and no negative Auswirkungen on the Knochenstoffwechsel hat, were invested by normal Serum marker for Knochenbildung and -resorption was invested (6).

AGAMREE (Vamorolon), an Arzneimittel for seltene Krankheiten, ist in de USA (prescribing information), de European Union (Zusammenfassung der Merkmale des Arzneimittels) und Vereinigten Königreich voor de Anwendung Zugelassen.

Literature reference:
(1) Dang UJ et al. (2024) Neurology 2024;102:e208112. doi.org/10.1212/WNL.0000000000208112. Link.
(2) Guglieri M et al. (2022). JAMA Neurol. 2022;79(10):1005-1014. doi:10.1001/jamaneurol.2022.2480. Link.
(3) Liu X et al. (2020). Proc Natl Acad Sci USA 117:24285–24293
(4) Heier CR et al (2019). Life Science Alliance DOI: 10.26508
(5) Ward et al., WMS 2022, FP.27 – Poster 71. Link.
(6) Hasham et al., MDA 2022 Posterpresentation. Link.

Uber Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy (DMD) is a selten, due to the X-Chromosome effect, that is quickly extracted from the body. DMD is a part that is used for burt or kurz danach auftritt. The treatment with a fibrosis of the musk tone is clinically clinical due to the enhanced musk generation and rush. The weight of the disease depends on the pleasure of the disease, the pleasure of self-healing, the beginning of the support of the disease and the disease of a cardiomyopathy. DMD reduces the life support of life and/or health for the four of their lives. Short steroids are the time standard for the treatment of DMD.

Uber Santhera
Santhera Pharmaceuticals (SIX: SANN) is a specialty pharmaceutical company engaged in the development and marketing of innovative drugs for neuromuscular development with a specialty drug. The alternative consists of an exclusive Lizenz from ReveraGen for all indications for AGAMREE® (Vamorolon), a dissoziative steroid with new artificial intelligence, which is being investigated in a certain disease study in patients with Duchenne Muscular Dystrophy (DMD) as an alternative to standard corticosteroids. AGAMREE for the treatment of DMD is approved in the US by the US-American Food and Drug Administration (FDA), in the EU by the European Arzneimittelbehörde (EMA) and in the United States by the Medicines and Healthcare products Regulatory Agency (MHRA)- zugelassen. Santhera has established an AGAMREE for North America, Catalyst Pharmaceuticals, Inc. and for China and Sperogenix Therapeutics. For more information, please visit www.santhera.de.

AGAMREE® is one of the flagship products of Marke von Santhera Pharmaceuticals.

Uber Ali Al Suwaidi Trading Est (ASTE)
ASTE is one of the distributors in Qatar with a 42-year business in the industry. The Unternehmen, who were found in katarichem Besitz, believe in the Gesundheitsektor with Arzneimitteln, Medizin- und Laborgeräten. Through selective partners, the ASTE is the best, latent business knowledge to recognize and test innovative and efficient products and services, an efficient system to provide. The Vision of ASTE is a sustainable partner for solutions in the healthy health and well-being of people, positive health and well-being and human well-being.
ASTE strives to stimulate and revive the region’s healthcare sector by enhancing innovative business activities.

For more information you can say:
(email protected) Oder
Andrew Smith, Finance Director
(email protected)

Haftungsausschluss / Zukunftsgerichtete Aussagen
This Mitteilung again states that there is no information regarding the approval of the Zeichnung or the purchase of Wertpapers from Santhera Pharmaceuticals Holding AG. This publication can bring the best results in the field of economics and the development of the state system. Solche-aussagen are mit de best risks, unsicherheiten und einem faktoren-linken, die sich tatsächlichen ergebnisse, de financing, de leistungen oder errungenschaften des errungenschaften des onternehmens sich er sich es, die in de sollchen-aussagen zum ausdruck were brought or implied. The teachers believe that they are not in trouble with these foreign people, but they will not be separated with investments or investments in the future. If the device no longer provides light, these targeted actions are intended to be activated.

# # #

Anhang

Quelle Hugin